SWEEP
6.9.2022 09:54:37 CEST | Business Wire | Press release
Sweep, the leading carbon management and reduction platform, today announced it has expanded its leadership team with the recruitment of former French Minister of Agriculture and Food Julien Denormandie as Chief Impact Officer. He officially joined on September 5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005500/en/
Julien Denormandie (Photo: Cheick Saidou)
Julien Denormandie said: "I am thrilled to start this new chapter at Sweep. Recent years, and especially the last few months, have shown us that the fight against climate change is the challenge of the century. It also reminded us of the need to develop concrete, applicable solutions that generate results. Sweep perfectly aligns with this virtuous approach by helping companies to measure and reduce their carbon emissions. In my new role as Chief Impact Officer, I want to use my experience, coupled with the market-leading tools that Sweep has created, to support businesses in their climate journey and become agents of positive change in the low carbon economy.”
Julien Denormandie will work alongside Sweep’s four co-founders to pursue the efforts that have already established the French start-up as one of the fastest-growing climate tech firms and a trusted partner to organisations around the world.
The challenges of reducing carbon emissions are both related to the massive amount of data that needs to be collected and evaluated, and to network issues due to the vast number of stakeholders involved. Julien will be in charge of strengthening Sweep’s network approach to carbon management to help maximise the impact of their climate action. His remit will also include growing the business, both in France and internationally, and further establishing Sweep’s position as a leading partner to organisations committed to a low-carbon future.
Rachel Delacour, CEO and co-founder of Sweep said, "The challenge of reversing the spiral of climate change is massive. Our ambition is to help organisations transition to a model that will thrive in a low carbon economy. Julien Denormandie's arrival is at the heart of this ambition. He joins at a time when Sweep is entering a new stage of its growth and I am delighted that we will continue to develop our platform and offer together. He has a unique ability to solve complex, multidimensional problems, which is the very essence of the challenges facing organisations when reducing carbon emissions today. This is in Sweep's DNA and Julien's too!”
Minister of Agriculture and Food from July 2020 to May 2022 in Jean Castex's government, Julien Denormandie was previously Deputy to the Minister of Territorial Cohesion in the government of Edouard Philippe between June 2017 and October 2018 and then Minister in charge of Cities and Housing until July 2020. He was successively advisor to the Minister in charge of Foreign Trade, Nicole Bricq, to the Minister of Economy and Finance, Pierre Moscovici before becoming Deputy Chief of Staff of the Minister of Economy, under Emmanuel Macron between 2012 and 2016. Ingénieur des ponts, des eaux et des forêts, he began his career on secondment to the Department of External Relations of the Ministry of the Economy before holding various positions at the French Embassy in Cairo and at the Treasury Department.
About Sweep
Sweep helps businesses track and act on their carbon so they can become forever companies.
The data-driven platform makes it easy to understand, manage and reduce your carbon footprint. Powerful collaboration features and user-focused design empower your staff and your entire value chain to grow a cleaner business. The platform also has an integrated marketplace, letting you contribute to exciting carbon reduction and removal projects around the world. And with all your data in one place, its analytics offer deep insights into your progress and automatic reporting to your stakeholders.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition and The International Emissions Trading Association. Visit sweep.net to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom